Loading clinical trials...
Loading clinical trials...
A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
Conditions
Interventions
tazemetostat
HMPL-689
Locations
1
China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Start Date
February 13, 2023
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2024
Last Updated
January 22, 2025
NCT06756321
NCT06532643
NCT05400876
NCT05271279
NCT02259010
NCT02214147
Lead Sponsor
Hutchmed
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions